Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 14/20 | 0.53 |
| ▸ | ABCC8 | Q09428 | 14/20 | 0.53 |
| ▸ | KCNJ11 | Q14654 | 14/20 | 0.53 |
| ▸ | KCNJ8 | Q15842 | 14/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12332113 | 0.74 | ABCC9 (0.55) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2449432 | 0.73 | ABCC9 (0.48) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2486122 | 0.72 | ABCC9 (0.47) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL12332293 | 0.72 | ABCC9 (0.46) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2449803 | 0.72 | ABCC9 (0.46) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL12332139 | 0.72 | ABCC9 (0.46) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2448360 | 0.72 | ABCC9 (0.46) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2451148 | 0.71 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2448630 | 0.71 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2448974 | 0.71 | ABCC9 (0.48) | ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237891-B1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | claimed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | claimed |
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S (US) | 2004-04-01 | — | — | US | claimed |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | PEDESTRIAN CONCEPTS LLC | 2003-01-30 | — | — | US | claimed |
| EP-1237891-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | claimed |
| EP-1237891-B1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S | 2007-05-03 | — | — | US | disclosed |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S | 2007-05-03 | — | — | US | disclosed |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S | 2007-05-03 | — | — | US | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S (US) | 2004-04-01 | — | — | US | disclosed |
| US-6706720-B2 | TREATMENT OF ARRHYTHMIA; INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | PEDESTRIAN CONCEPTS LLC | 2003-01-30 | — | — | US | disclosed |
| EP-1237891-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNH2, KCNH1 | ABCC9 297/4885ABCC8 292/4885KCNJ11 21/4885 |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNH2, KCNH1 | ABCC9 297/4885ABCC8 292/4885KCNJ11 21/4885 |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNQ5, KCNQ2 | ABCC9 246/4885ABCC8 268/4885KCNJ11 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.